Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC

INTRODUCTION: Immune checkpoint inhibitors (ICIs) induce long-term, durable responses in patients with advanced NSCLC. Nevertheless, these responses are limited to a few patients, and most responders have disease progression. The purpose of this study was to determine the differences in clinical fac...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Hitomi, Yoshida, Tatsuya, Yagishita, Shigehiro, Ohuchi, Mayu, Matsumoto, Yuji, Shinno, Yuki, Okuma, Yusuke, Goto, Yasushi, Horinouchi, Hidehito, Yamamoto, Noboru, Takahashi, Kazuhisa, Motoi, Noriko, Hamada, Akinobu, Ohe, Yuichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050777/
https://www.ncbi.nlm.nih.gov/pubmed/37007867
http://dx.doi.org/10.1016/j.jtocrr.2023.100474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050777/
https://www.ncbi.nlm.nih.gov/pubmed/37007867
http://dx.doi.org/10.1016/j.jtocrr.2023.100474

Ejemplares similares